Circuit-Bio
Platform of Logical Gene Circuits for Cancer Immunotherapy
Company Overview
Snapshot
Founded in April 2020 by Nir Skalka, Circuit-Bio operated with 1–10 employees. The company secured seed funding in one round from two investors. In February 2025, Circuit-Bio ceased operations.
Business overview
Circuit-Bio is a synthetic biology company focused on developing a unique platform of logical gene circuits for cancer immunotherapy. The company's technology generates gene circuits that locally and accurately produce a combination of multiple immune-stimulating proteins, exclusively expressed in targeted tumor cells. This approach aims to convert cancer cells into 'Trojan horses' to trigger a robust, long-term anti-tumor immune response. The immunomodulators' output is controlled by two de novo synthetic cancer-specific promoters (SPECS), enabling multi-output gene expression only when both synthetic promoters are activated simultaneously. Circuit-Bio's bio-convergence approach differentiates itself from other immunotherapy treatments by offering a tunable mode of action, addressing obstacles in immunotherapeutic drug treatment. The modularity of the circuit allows for adaptation of components to specific indications, such as selecting effective tumor-specific immunomodulator combinations. The company operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.
Company Intelligence Q&A
- What is Circuit-Bio's primary focus?
- Circuit-Bio is a synthetic biology company developing a platform of logical gene circuits for cancer immunotherapy.
- When was Circuit-Bio founded?
- Circuit-Bio was founded in April 2020.
- Who founded Circuit-Bio?
- Circuit-Bio was founded by Nir Skalka.
- What is the core technology behind Circuit-Bio's platform?
- Circuit-Bio's platform focuses on generating gene circuits that locally and accurately produce a combination of multiple immune-stimulating proteins, exclusively expressed in targeted tumor cells, controlled by two de novo synthetic cancer-specific promoters (SPECS).
- What is the current status of Circuit-Bio?
- Circuit-Bio ceased to operate in February 2025.